Following up the early U.S. approval of in-licensed Beleodaq (belinostat) for peripheral T-cell lymphoma, Spectrum Pharmaceuticals Inc. offered good news from another deal, making public the plans to push SPI-2012, a long-acting granulocyte stimulating factor (GCSF), into phase III trials next year.